Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Carvykti ciltacabtagene autoleucel Relapsed or refractory multiple myeloma Pending
TBC leniolisib Activated phosphoinositide 3 kinase delta syndrome Pending
TBC pegcetacoplan Geographic atrophy secondary to age-related macular degeneration Pending
Admelog Insulin lispro Cancelled
TBC filgrastim Cancelled
Xeljanz tofacitinib Cancelled
TBC exagamglogene autotemcel Transfusion-dependent β-thalassemia Pending
TBC exagamglogene autotemcel Sickle cell disease (SCD) Pending
Translarna ataluren Cancelled
TBD Trastuzumab Cancelled